BioSpace News Archive

Novotech, the leading Asia Pacific centred biotech CRO with global execution capabilities, announced that Dr. Yooni Kim, Vice President of Clinical Services at Novotech, served as a keynote speaker at the Veeva Korea Summit this week in Seoul, Korea.

The medical and technology teams at Bactiguard have, together with KTH, Sweden’s largest technical university, and Karolinska Institute, performed a study on the impact of using Bactiguard’s noble metal coating to reduce thrombo-inflammatory reactions and acute stent thrombosis.

AbbVie announced that its Phase 2b study evaluating upadacitinib in adults with non-segmental vitiligo met the primary endpoint of percent change from baseline in the Facial Vitiligo Area Scoring Index at week 24 with the 11 mg and 22 mg doses versus placebo.

Smart Immune, a clinical-stage biotechnology company developing ProTcell, a thymus-empowered T-cell progenitor therapy platform to fully and rapidly re-arm the immune system, announced a series of activities in and around the European Society of Gene and Cell Therapy 30th Annual Congress being held in Brussels, Belgium from October 24-27, 2023.

West Pharmaceutical Services, Inc., a global leader in innovative solutions for injectable drug administration, announced that it will release third-quarter 2023 financial results before the market opens on Thursday, October 26, 2023, and will follow with a conference call to discuss the results and business expectations at 9:00 a.m. Eastern Time.

Eli Lilly and Company announced that mirikizumab met the co-primary and all major secondary endpoints compared to placebo in VIVID-1, a Phase 3 study evaluating the safety and efficacy of mirikizumab for the treatment of adults with moderately to severely active Crohn’s disease.

RVL Pharmaceuticals plc today announced to effectuate a change of control transaction through prepackaged bankruptcy cases commenced in the United States Bankruptcy Court for the District of Delaware today (the “Reorganization”).

Sun Pharmaceutical Industries Limited (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, “Sun Pharma” and includes its subsidiaries and/or associate companies) today announced the presentation of Phase 4 data showing that CEQUA® (cyclosporine ophthalmic solution) 0.09% induces sustained improvement in the signs and symptoms of dry eye disease (DED).

Coave Therapeutics announces the formation of its new Scientific Advisory Board (SAB) comprising renowned leaders in gene therapy, neurological diseases, adeno-associated viral (AAV) and non-viral vector technologies.

Helius Medical Technologies, Inc. announced that it has received a letter of intent from the Québec Ministry of Health and Social Services for the purchase of 30 Portable Neuromodulation Stimulator devices as part of an initiative to assess the value of using PoNS to treat patients suffering symptoms due to stroke.